Symposia: Aggressive Lymphomas: Pharmacologic Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Combination therapy, Non-Hodgkin lymphoma, Lymphomas, Bispecific Antibody Therapy, Assays, Drug development, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Biological therapies, Treatment Considerations, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Technology and Procedures, Human, Study Population, Measurable Residual Disease , Imaging, Molecular testing
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Combination therapy, Non-Hodgkin lymphoma, Lymphomas, Bispecific Antibody Therapy, Assays, Drug development, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Biological therapies, Treatment Considerations, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Technology and Procedures, Human, Study Population, Measurable Residual Disease , Imaging, Molecular testing
Sunday, December 8, 2024: 12:00 PM-1:30 PM
Ballroom 20AB
(San Diego Convention Center)
Moderators:
Eliza A. Hawkes, MD, Austin Health
and
Matthew Matasar, MD, MS, Rutgers
Disclosures:
Hawkes: AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Research Funding, Speakers Bureau; Merck KGaA: Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck Sharpe and Dohme: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Antengene: Membership on an entity's Board of Directors or advisory committees; Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; Regeneron Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Speakers Bureau. Matasar: Bayer: Consultancy, Honoraria, Research Funding; Merck: Current equity holder in publicly-traded company; Allogene: Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees; GM Biosciences: Consultancy, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Johnson & Johnson: Consultancy, Honoraria, Research Funding; Immunovaccine Technologies: Research Funding; ADC Therapeutics: Honoraria; AstraZeneca: Honoraria; BMS/Celgene: Honoraria; Kite: Honoraria; Epizyme: Honoraria; IMV Therapeutics: Honoraria; Pfizer: Honoraria; Takeda: Honoraria; Regeneron Pharmaceuticals, Inc.: Honoraria.
Presentations in this session focus on novel therapies combined with standard immunochemotherapy such as RCHOP or PolaR-CHP in newly diagnosed Diffuse Large B cell Lymphoma
12:00 PM
12:15 PM
12:30 PM
12:45 PM
1:00 PM
1:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH